tiprankstipranks
Advertisement
Advertisement
CytoSorbents Receives Nasdaq Extension to Regain Compliance
PremiumCompany AnnouncementsCytoSorbents Receives Nasdaq Extension to Regain Compliance
3M ago
Cytosorbents’ Earnings Call Balances Progress and Risk
Premium
Company Announcements
Cytosorbents’ Earnings Call Balances Progress and Risk
3M ago
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
Premium
Ratings
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
3M ago
CytoSorbents sees FY25 revenue $37M, consensus $37.67M
PremiumThe FlyCytoSorbents sees FY25 revenue $37M, consensus $37.67M
6M ago
Cytosorbents Corp’s Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Cytosorbents Corp’s Earnings Call: Growth Amid Challenges
8M ago
CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright
Premium
The Fly
CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright
8M ago
Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?
PremiumCompany AnnouncementsCytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?
8M ago
CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update
Premium
Company Announcements
CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update
8M ago
Cytosorbents Faces Nasdaq Non-Compliance Notice
Premium
Company Announcements
Cytosorbents Faces Nasdaq Non-Compliance Notice
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100